USA News Group
Commentary
Issued on behalf of BioVaxys Technology Corp.
VANCOUVER, BC, Aug. 19,
2024 /CNW/ -- USA
News Group – How we take care of the planet, and the food we
eat is rapidly shifting. Back in May, the World Economic
Forum addressed how countries are redefining their bioeconomy
for the future, with each aiming for sustainable solutions. NGOs
around the world are calling for urgent action to accelerate
nature-based solutions to tackle global challenges, while the
World Bank is encouraging sustainable agriculture, not an
end to farming. Behind the scenes, several biotech firms are
working on solutions that can help foster these types of goals,
including BioVaxys Technology Corp. (CSE: BIOV) (OTCQB:
BVAXF), Zoetis Inc. (NYSE: ZTS), Corteva, Inc. (NYSE:
CTVA), Bunge Global SA (NYSE: BG), and BRF S.A.
(NYSE: BRFS).
Earlier this year, the clinical-stage biotech company
BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) made
headlines with its strategic acquisition of a comprehensive
clinical development pipeline, which includes the cutting-edge DPX™
immune system educating antigen delivery platform. BioVaxys
identified DPX™ as a potential game-changing enabling technology
across several areas, including improved mRNA vaccines, multivalent
viral vaccines, cancer vaccines, and treatments for immune system
disorders. But these uses aren't restricted just to human, as
BioVaxys recognizes that animal biotech has a faster
regulatory pathway than humans.
Partnered with SpayVac for Wildlife (SpayVac), the two
companies recently announced the completion of a new expanded
research and production facility in Madison, Wisconsin to produce SpayVac's
long-lasting, single-dose veterinary contraceptive vaccines. Thanks
to BioVaxys' patented liposome-based antigen delivery
platform technology, SpayVac can address the significant
fertility-control needs in wildlife, agricultural production
animals, and aquaculture markets, setting up the potential for
BioVaxys to attain royalty revenue from the project in
2025.
"This new laboratory will significantly enhance our ability to
develop new vaccine formulations for species that would benefit
from humane, long-term fertility control," said Dr. Ursula Bechert, Vice-President of Research and
Development for SpayVac for Wildlife.
SpayVac is preparing to commercialize fertility
control vaccines for deer, horses, and other animals, utilizing the
patented liposome-based delivery platform technology licensed from
BioVaxys.
"I'm enthusiastic about the many benefits of this space," said
Tom D'Orazio, CEO of SpayVac for Wildlife. "It is flexible
enough for us to do both our research and small-scale production.
The facility has a number other biopharma tenant companies,
such as Kendrick Laboratories and Plumb Pharmaceuticals, creating a
biotech hub and collaborative environment."
SpayVac originally operated out of the University of Victoria in British Columbia but relocated to
Madison, Wisconsin, following the
pandemic. Backed by the BrightStar Wisconsin Foundation and
angel investors, SpayVac successfully expanded its
laboratory and secured space in a facility owned by Lytic
Solutions. This new location will enable the company to produce
vaccines for both ongoing and future experimental contraceptive
trials.
"With our licensee SpayVac on track for submitting their
filing for regulatory approval in 2025, they expect to see
commercial sales, which will generate royalty revenue from
our liposome-based antigen delivery platform technology," said
Kenneth Kovan, President & Chief
Operating Officer of BioVaxys.
Though it's being initially implemented for deer, horses, etc.,
the potential for BioVaxys' antigen delivery platfrom is
quite large, in particular in the growing commercial aquaculture
vaccines market. Back in April, BioVaxys and SpayVac
announced a joint effort in the aquaculture space to field
test single-dose, long-lasting immune-contraceptives in farmed
rainbow trout—a market that's projected to reach US$7 billion by 2033. As a side note, the duo has
also teamed up to test a long-lasting, single-dose contraceptive
vaccine, in captive Asian elephants, with a clinical study
current,y ongoing in Thailand.
When BioVaxys acquired IMV, Inc., it also acquired
milestone payments and a royalty bearing license
agreement with Zoetis Inc. (NYSE: ZTS), the world's
largest producer of medicine and vaccinations for pets and
livestock, for their development and sale of various animal health
products using BioVaxys antigen delivery technology.
Zoetis recently released its Q2 2024 results, which
included revenue growth of 8% to $2.4
billion, and 11% operational growth in revenue. Sales of
livestock products increased 11% in the quarter, with notable
growth in both cattle and swine products year-over-year.
"We had another outstanding quarter, demonstrating the strong
demand for our trusted, innovative products, our ability to capture
and expand markets, and the dedication of our purpose-driven
colleagues," said Kristin Peck, CEO
of Zoetis. "We achieved 12% revenue growth in the U.S. and
10% operational revenue growth internationally, with both our
companion animal and livestock portfolios seeing impressive global
operational growth, 12% and 9% respectively."
Earlier in the year, Zoetis expanded its stock vaccine
production footprint through an 8-hectare land purchase for a new
manufacturing site in Melbourne,
Australia. It also launched GlanEry 7in1 B12, a new
innovation in sheep vaccines. Each of these innovations is in line
with Zoetis' commitment to healthier animals and sustainable
agriculture.
Corteva Agriscience, a wholly-owned subsidiary of global
agriculture company Corteva, Inc. (NYSE: CTVA) recently
began its promotion of the Direct Seeded Rice (DSR) technique,
where rice seeds are directly sown into the field against the
traditional method involving seedling nurseries and transplants.
The strategy recognizes the urgent need for sustainable and
innovative agricultural solutions to address environmental
challenges, while providing economic benefits.
"We're committed to developing innovative solutions for enhanced
DSR adoption in India,"
said Dr. Raman Babu, Seed
Research and Development Leader, South
Asia, for Corteva Agriscience. "Our focus remains on
developing superior climate resilient DSR seed products, crop
protection innovations and agronomic excellence that will
contribute to solutions for water scarcity and climate variability,
ultimately fostering a more sustainable and productive future for
India's rice production."
For reference, India is one of
the world's largest rice producers, accounting for over 20% of
global production, and its rice market is valued at an estimated
US$52.8 billion. However, export
restrictions on Indian rice continue to disrupt global markets,
supplies, and prices.
Agrobusiness giant Bunge Global SA (NYSE: BG) recently
teamed up with Thai conglomerate CP Foods to test a
blockchain-powered traceability platform for shipments of
deforestation-free soybean meal. As of June
2024, the two companies had so far shipped three vessels
totalling 185,000 metric tons of soybean meal from Brazil to Thailand, with the products fully traceable
from farm origin to final delivery.
"Adding a layer of blockchain technology improves the
transparency in end-to-end traceability that Bunge has been doing
for some years," said Rossano de Angelis
Jr, Vice President of Agribusiness, South America, of Bunge. "This ability
to increase end-consumer confidence in soy projects is only
possible thanks to the robust supplier's socio-environmental
verification and monitoring system that we have structured over the
last decade."
The eco-conscious approach to soy has reached Brazilian pork and
chicken processor BRF S.A. (NYSE: BRFS), which earlier in
August was reported to be willing to pay a 2% premium from market
prices for soybeans produced through regenerative agricultural
practices. Regenerative agriculture focuses on enhancing soil
health and boosting productivity by employing methods like crop
rotation and organic fertilization.
The project is being managed by a consortium that includes
BRF, Germany's Bayer
AG, a number of Brazilian companies, and a local research
group. Produzindo Certo, a company specializing in
establishing sustainable agricultural supply chains and part of the
consortium, anticipates that within a year, the project will
encompass 30 soy farms—expected to produce over 200,00 metric tons
of soybeans verified as regenerative.
Meatpackers like BRF use soymeal derived from these
soybeans to feed their livestock. Bayer will play a key role
in the project by supplying tools to assess the advantages farmers
achieve through the adoption of regenerative agricultural
practices.
Article Source:
https://biotech-insider.com/the-phoenix-of-biotech-how-a-6m-junior-just-swooped-into-a-potential-billion-dollar-opportunity/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for BioVaxys Technology Corp. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares of BioVaxys Technology Corp., and may liquidate their
shares which could have a negative effect on the price of the
stock. This compensation constitutes a conflict of interest as to
our ability to remain objective in our communication regarding the
profiled company. Because of this conflict, individuals are
strongly encouraged to not use this publication as the basis for
any investment decision. The owner/operator of MIQ own shares of
BioVaxys Technology Corp. which were purchased in the open market,
and reserve the right to buy and sell, and will buy and sell shares
of BioVaxys Technology Corp.at any time without any further notice
commencing immediately and ongoing. We also expect further
compensation as an ongoing digital media effort to increase
visibility for the company, no further notice will be given, but
let this disclaimer serve as notice that all material, including
this article, which is disseminated by MIQ has been approved by
BioVaxys Technology Corp.; this is a paid advertisement, we
currently own shares of BioVaxys Technology Corp. and will buy and
sell shares of the company in the open market, or through private
placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between the any predictions and actual
results. Always consult a licensed investment professional before
making any investment decision. Be extremely careful, investing in
securities carries a high degree of risk; you may likely lose some
or all of the investment.
View original
content:https://www.prnewswire.com/news-releases/sustainable-agriculture-the-growing-need-for-biotech-innovations-in-the-worlds-food-supplies-302225474.html
SOURCE USA News Group